Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 42.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 181,674 shares of the company’s stock after buying an additional 54,031 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Kura Oncology were worth $3,875,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of KURA. BVF Inc. IL boosted its holdings in Kura Oncology by 9.5% during the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after buying an additional 642,245 shares in the last quarter. Vanguard Group Inc. increased its stake in Kura Oncology by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company’s stock valued at $35,791,000 after purchasing an additional 275,173 shares in the last quarter. Armistice Capital LLC raised its holdings in Kura Oncology by 5.3% during the third quarter. Armistice Capital LLC now owns 2,236,000 shares of the company’s stock worth $20,392,000 after purchasing an additional 112,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Kura Oncology by 10.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock worth $28,785,000 after purchasing an additional 197,530 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in Kura Oncology by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,353,665 shares of the company’s stock valued at $19,466,000 after purchasing an additional 130,710 shares during the last quarter.

Kura Oncology Stock Up 0.4 %

NASDAQ KURA opened at $20.59 on Friday. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $20.82 and its 200 day moving average price is $19.33. Kura Oncology, Inc. has a twelve month low of $7.41 and a twelve month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.50) EPS. Research analysts expect that Kura Oncology, Inc. will post -2.56 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In related news, insider Teresa Brophy Bair sold 2,615 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the sale, the insider now directly owns 68,979 shares in the company, valued at approximately $1,527,884.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Monday, June 24th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, May 3rd. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Tuesday, June 18th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.36.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.